Beximco Launches First Remdesivir Generic
World’s First Generic Version Of COVID-19 Treatment Introduced In Bangladesh
Bangladesh's Beximco has claimed a world first with the launch of a generic version of remdesivir in its domestic market. Local authorities have granted an emergency use authorization for the COVID-19 treatment amid the coronavirus pandemic.
You may also be interested in...
Bangladeshi generics manufacturer Beximco has reported 12.3% annual sales growth for its 2020 financial year and 9.9% turnover growth for its financial first quarter ending 30 September 2020. The company remains focused on expanding its portfolio and consolidating its international presence.
In the third and final part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies, one or two new entrants appeared towards the bottom of the top 50.
Lauding a “significant milestone for Mylan, for the global public health community and, most importantly, for patients who are battling this pandemic,” Mylan has received approval in India for its remdesivir 100mg/vial product licensed from Gilead Sciences.